Development
Dyne Therapeutics, Inc.
DYN
$11.59
$1.1210.70%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -40.36% | -14.95% | -3.87% | -10.50% | -12.60% |
| Total Depreciation and Amortization | -0.59% | 3.20% | 10.43% | 30.98% | 54.69% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.09% | -9.64% | -20.20% | -21.66% | -6.37% |
| Change in Net Operating Assets | 589.07% | -12.76% | -116.17% | 157.49% | -158.11% |
| Cash from Operations | -22.46% | -19.55% | -27.72% | 1.38% | -28.51% |
| Capital Expenditure | 76.23% | 74.31% | 58.42% | 62.16% | 15.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6.90% | 7.26% | 559.31% | 1,880.76% | 167.23% |
| Cash from Investing | -4.46% | 12.73% | 771.06% | 1,098.88% | 163.24% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 45.28% | 33,007.97% | 13,624.59% | 11,137.18% | -76.31% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 45.28% | 33,007.97% | 13,624.59% | 11,137.18% | -76.31% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -73.91% | 82.71% | 125.77% | 120.11% | 70.84% |